takeda-pharmaceuticals-international-gmbh

Médias

Takeda Launches New Subsidiary in Israel

Médias

Takeda Drives Leading PAMES Study in Brazil Showing Improved Symptom Relief for People with Erosive Gastroesophageal Reflux Disease (GERD)

Médias

Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone - A New Atypical Antipsychotic Treatment for Adults with Schizophrenia

Médias

Un informe destaca la importancia de reducir el riesgo en el tratamiento de la COPD

Médias

Un nouveau rapport souligne l'importance accrue de la réduction des risques dans la prise en charge de la bronchopneumopathie chronique obstructive (BPCO)

Médias

New Report Highlights Increased Importance of Risk Reduction in Chronic Obstructive Pulmonary Disease (COPD) Management